GOG GYN-LIVE
Welcome to the official podcast of The GOG Foundation, Inc.—a nonprofit organization dedicated to advancing excellence in clinical and scientific research for gynecologic cancers. From ovarian and uterine to cervical, vaginal, and vulvar malignancies, our investigators and institutions are at the forefront of innovation, shaping the future of cancer care. Each episode features leading experts, groundbreaking trial insights, and real-world stories that illuminate the evolving landscape of gynecologic oncology. Whether you're a clinician, researcher, patient advocate, or survivor, join us as we explore the science, the people, and the progress driving better outcomes and quality of life for patients ev...
10
GOG-3103/ ENGOT-ov84/ TroFuse-022 Clinical Trial Update
GOG-3073/ ENGOT-ov72/ APGOT-Ov10/ LACOG-0223/ ROSELLA FDA APPROVAL PODCAST
InnovaTV 205 GOG-3024/ENGOT-cx8 Publication Podcast
Uterine Cancer Awareness Month 2026 Podcast
Accrual Culture: Top Points for Site Selection - Timelines
<p>The GOG Foundation, Inc. would like to thank our commercial supporters for their support of the GOG GYN-LIVE Podcast:<br>Corcept Therapeutics, GSK, Pfizer Oncology, Eli Lilly, Genmab, and Verastem</p> ★ Support this podcast ★
Accrual Culture: Top Points for Site Selection - Responsiveness
GOG-3101 | TroFuse-20 Clinical Trial Update
<p>In this episode, we dive into GOG‑3101 TroFuse‑20—a Phase 3, randomized, active‑controlled, open‑label, multicenter study evaluating MK‑2870 monotherapy versus Treatment of Physician’s Choice as second‑ or third‑line therapy for patients with recurrent or metastatic cervical cancer.</p> ★ Support this podcast ★
The GOG Highlight Reel - January 2026
<p>The GOG Foundation, Inc. and GOG Partners are thrilled to present the “The GOG Highlight Reel”, an ongoing Education Series that showcases clinical trials and other newsworthy education, from major medical meetings throughout the year. </p><p>The GOG Highlight Reel distills practice-changing information disclosed during recent major medical meetings into a two-and-a-half-hour segment. This comprehensive course examines recent clinical trial data in gynecologic malignancies, offering insights on data presentations, ongoing research, and drug approvals shaping the field. It addresses common gynecologic malignancies, aiding physicians in comprehending the evolving treatment landscape, including understanding trials in progress. Participants will receive a syn...
KEYNOTE-B96 FDA APPROVAL REVIEW
Accrual Culture: Top Points for Site Selection - Feasibility
